![]() |
Novartis Inks Agreement For Immunogen's "TAP" ADC Technology
|
Re: Novartis Inks Agreement For Immunogen's "TAP" ADC Technology
Excellent news, especially since Novartis has so many breast cancer therapies in the pipeline. Hopefully this will lead to more ADC treatments. Perhaps this time, they can link a less toxic chemo with a MAB and increase both quantity and Quality of life.
|
| All times are GMT -7. The time now is 03:18 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021